Glurenorm (Gliquidone)

Glurenorm is a prescription oral medication containing the active ingredient gliquidone, a sulfonylurea class antidiabetic agent. It is marketed in the European Union for the management of type 2 diabetes mellitus. The product is supplied as tablets (strength not specified) and works by stimulating insulin release from pancreatic beta cells. It is usually prescribed when diet, exercise, and other oral agents are insufficient, and is taken once daily with meals.

Glurenorm (gliquidone) is indicated for the oral management of type 2 diabetes mellitus in adults. It may be used as monotherapy or in combination with other antidiabetic agents when glycemic targets are not met with lifestyle measures alone.

- Improves fasting and post‑prandial blood glucose levels. - Can be combined with metformin, thiazolidinediones, or DPP‑4 inhibitors under medical supervision. - May be considered when sulfonylurea therapy is appropriate for patients with preserved pancreatic beta‑cell function. - Used as part of a comprehensive diabetes care plan that includes diet, exercise, and regular monitoring.

Like other sulfonylureas, gliquidone may cause a range of adverse effects, most of which are dose‑related and reversible after discontinuation.

Common: - Mild hypoglycemia, especially if meals are delayed or missed. - Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia. - Skin reactions including rash or pruritus. - Weight gain due to increased insulin activity.

Serious: - Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness). - Allergic reactions such as angioedema or Stevens‑Johnson syndrome. - Hepatic dysfunction manifested by elevated transaminases. - Hematologic abnormalities like leukopenia or thrombocytopenia.

Before initiating Glurenorm, clinicians should evaluate patient history and laboratory parameters to minimize risk of adverse outcomes.

- Assess renal and hepatic function; dose adjustment may be required in impairment. - Verify that the patient has adequate pancreatic beta‑cell reserve. - Caution in elderly patients due to increased susceptibility to hypoglycemia. - Avoid use during acute illness, fasting, or excessive alcohol consumption. - Review concomitant medications that may potentiate hypoglycemia. - Counsel patients on recognizing early signs of low blood sugar. - Discontinue if recurrent severe hypoglycemia occurs.

Glurenorm can interact with several drug classes, altering its hypoglycemic effect or increasing the risk of adverse reactions.

Avoid: - Other sulfonylureas or meglitinides (additive hypoglycemia risk). - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that may raise gliquidone levels. - High‑dose salicylates (enhanced insulin release).

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - ACE inhibitors or ARBs, which can potentiate hypoglycemia in renal impairment. - Thiazide diuretics, which may affect glucose tolerance. - Anticoagulants, as hypoglycemia can alter INR stability.